Efficacy of Transcranial Static Magnetic Field Stimulation (tSMS) in Amyotrophic Lateral Sclerosis (ALS).

Study Purpose:

This study aims to evaluate safety and efficacy of tSMS in ALS patients and to obtain preliminary data about the effects of tSMS on cortical excitability.

To this purpose, 40 ALS patients will be recruited and randomized to real or sham tSMS. After at least 3 months follow-up, they will undergo tSMS, daily for 120 min, at home, for 6 consecutive months.

Clinical status will be tested before, during and after the stimulation period. Moreover, cortical excitability will be tested by transcranial magnetic stimulation (TMS) before and after the stimulation period.

Study Status:

Recruiting

Disease:

Amyotrophic Lateral Sclerosis

Study Type:

Interventional

Type of Intervention:

Device

Intervention Name:

tSMS, sham tSMS

Placebo:

Phase:

N/A

Study Chair(s)/Principal Investigator(s):

N/A

Clinicaltrials.gov ID:

NCT04393467

Neals Affiliated?

No

Coordinating Center Contact Information

Study Sponsor:

Campus Bio-Medico University

Estimated Enrollment:

40

Estimated Study Start Date:

05 / 31 / 2020

Estimated Study Completion Date:

12 / 01 / 2023

Posting Last Modified Date:

10 / 19 / 2020

Date Study Added to neals.org:

05 / 19 / 2020

Minimum Age:

18 Years

Maximum Age:

75 Years

Inclusion Criteria:

- age between 18 and 75 years

- diagnosis of ALS according to revised El Escorial criteria and Awaji-Shima criteria

- disease duration < 24 months

- ALSFRS-R > 30 at the recruitment

- ALSFRS-R decline > 1 in the at least 3-months period before the intervention

- normal respiratory functionality (FVC > 80% and ALSFRS-R items 10,11,12 > 4) at the recruitment

- treatment with riluzole 50 mg x 2/die

Exclusion Criteria:

- inclusion in other clinical trials

- presence of tracheotomy or/and PEG (percutaneous endoscopic gastrostomy)

- contraindications to magnetic fields exposure

- pregnancy or breast-feeding

- history of epilepsy or seizures

- assumption of drugs acting on central nervous system, except for antidepressive drugs and benzodiazepines.

- cognitive impairment

- lack of informed consent

Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS | Recruiting

Vincenzo Silani, MD / +39 02619111 / email hidden; JavaScript is required

Milan
Italy

Neurology Unit, Campus Biomedico University | Recruiting

Vincenzo Di Lazzaro, MD / +39 06 22541 1320 / email hidden; JavaScript is required

Sub-Investigator : Marilisa Boscarino, MD

Rome 00128
Italy